Inhaled therapy expansion MannKind focuses on inhaled therapeutics with Technosphere technology and has ongoing development of two FDA-approved dry powder inhalation therapies, presenting a clear opportunity to cross-sell inhalation device integration, remote monitoring, and patient support services to expand adoption in diabetes and cardiometabolic care.

Clinical data momentum Recent ADA 2026 presentations and real-world data for Afrezza across pediatric diabetes, automated insulin delivery systems, and gestational diabetes indicate growing evidence for inhaled insulin products, suggesting demand-driven engagement with endocrinology and pediatrics stakeholders.

Strategic partnerships Expanded license and collaboration with United Therapeutics for ralinepag DPI signals an active co-development model in pulmonary disease, presenting avenues to license, co-market, or integrate complementary inhaled therapies across cardiopulmonary portfolios.

Manufacturing capacity Danbury facility expansion and established manufacturing solutions imply readiness to scale production for additional inhaled therapies, enabling sales teams to discuss supply reliability, contract manufacturing opportunities, and global distribution capabilities.

Financial positioning With revenue in the mid-range of hundred millions and a biotech profile, MannKind represents a mid-sized partner for pharma and healthcare providers, offering opportunities for collaboration on clinical programs, payer strategies, and co-development financing to advance novel inhaled treatments.